Alnylam Pharmaceuticals, Inc.

As a reminder, today's conference call is being recorded.

I would now like to hand the conference over to the company. Please go ahead. Good morning.

I'm Christine Lindenboom, Senior Vice President from Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, Chief Executive Officer, Tolga Tanguilar, Chief Commercial Officer, Wishkel Garg, Chief Medical Officer, and Jeff Fulton, Chief Financial Officer. For those of you participating in the conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.alnylam.com slash events. During today's call, as outlined in slide two, Yvonne will provide introductory remarks and general contacts. Togo will provide an update on our global commercial progress. Pushko will review pipeline updates and clinical progress, and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call to your questions. I'd like to remind you that this call will contain remarks concerning LNILAM's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file with the FEC. In addition, any forward-looking statements represent our views only of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to Yvonne. Yvonne?